Stem Cell Therapy for Progressive Heart Failure Prevention
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for effective methods to prevent or treat progressive heart failure, particularly in patients with persistent left ventricular dysfunction and proximal left anterior descending (LAD) lesions following myocardial infarction (MI).
Innovation Solution
Administering a population of mesenchymal lineage precursor or stem cells, along with their progeny and soluble factors, to patients with proximal LAD lesions and persistent left ventricular dysfunction. The cells and factors are typically administered between 1 to 7 days post-MI, with a focus on those with elevated serum biomarkers and significant infarct size.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional post-MI treatment is provided to patients with proximal LAD lesions and large infarcts, then standard care is delivered, but these patients experience high rates of progressive LV dilatation, remodelling, and symptomatic heart failure
Solution Approach 1:
The patent applies local quality by identifying and targeting a specific subset of patients (those with proximal LAD lesions, large infarcts >18.5%, and low ejection fraction) rather than treating all MI patients uniformly. This selective approach focuses therapeutic resources on the population most likely to benefit from stem cell therapy, improving prevention efficacy while avoiding unnecessary treatment in lower-risk groups.
Solution Approach 2:
The patent implements preliminary action by administering stem cell therapy early in the post-MI period (within 24 hours to 7 days) to prevent progressive heart failure before it develops. This proactive intervention aims to stop the pathological process of LV dilatation and remodelling at its inception rather than treating established heart failure.
2Productivity
If stem cell therapy is administered to all MI patients, then broad coverage is provided, but the pronounced therapeutic improvement is diluted across populations who may not benefit
Solution Approach 1:
The patent enhances productivity by concentrating stem cell therapy on the specific high-risk population (proximal LAD lesions, large infarcts, low ejection fraction) who demonstrate pronounced therapeutic improvement. This focused approach maximizes the efficiency and impact of the therapy while avoiding dilution of benefits across broader populations with varying response rates.
Solution Approach 2:
The patent manages device complexity through preliminary patient stratification using established clinical criteria (infarct size >18.5%, ejection fraction thresholds, proximal LAD lesion identification) that can be determined through routine post-MI imaging and assessment. This pre-screening process identifies suitable candidates without requiring complex additional testing.
3Reliability
If early stem cell therapy is administered within 24 hours to 7 days post-MI, then prevention of progressive heart failure is optimized, but the treatment window is narrow and requires rapid patient identification
Solution Approach 1:
The patent optimizes prevention efficacy by establishing a clear treatment window (24 hours to 7 days post-MI) and implementing preliminary patient identification through routine post-MI imaging and clinical assessment. This structured approach ensures patients are identified and treated within the optimal timeframe for preventing progressive heart failure.
Solution Approach 2:
The patent addresses time loss by focusing resources on identifying patients with specific high-risk features (proximal LAD lesions, large infarcts) who require urgent intervention. This targeted approach prioritizes patients most likely to benefit from early therapy, streamlining the identification and treatment process within the narrow therapeutic window.
Data Source
AI summary
The present disclosure relates to methods for preventing progressive heart failure in subjects with persistent left ventricular (LV) dysfunction. Such methods may also be used for treating or preventing progressive heart failure in subjects with a proximal left anterior descending (LAD) lesion and persistent left ventricular dysfunction.